CORBUS PHARMACEUTICALS HLDGS's ticker is CRBP and the CUSIP is 21833P103. A total of 72 filers reported holding CORBUS PHARMACEUTICALS HLDGS in Q3 2017. The put-call ratio across all filers is 2.77 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $109,000 | +12.4% | 20,000 | 0.0% | 0.02% | +5.0% |
Q3 2019 | $97,000 | -32.6% | 20,000 | -3.8% | 0.02% | -31.0% |
Q2 2019 | $144,000 | +2.1% | 20,780 | +2.4% | 0.03% | 0.0% |
Q1 2019 | $141,000 | +18.5% | 20,300 | 0.0% | 0.03% | +7.4% |
Q4 2018 | $119,000 | -22.2% | 20,300 | 0.0% | 0.03% | -12.9% |
Q3 2018 | $153,000 | +48.5% | 20,300 | 0.0% | 0.03% | +55.0% |
Q2 2018 | $103,000 | -16.9% | 20,300 | 0.0% | 0.02% | -23.1% |
Q1 2018 | $124,000 | -13.9% | 20,300 | 0.0% | 0.03% | -10.3% |
Q4 2017 | $144,000 | -0.7% | 20,300 | 0.0% | 0.03% | -6.5% |
Q3 2017 | $145,000 | +11.5% | 20,300 | -1.7% | 0.03% | +3.3% |
Q2 2017 | $130,000 | -22.6% | 20,660 | +1.5% | 0.03% | -26.8% |
Q1 2017 | $168,000 | -0.6% | 20,360 | +1.8% | 0.04% | -12.8% |
Q4 2016 | $169,000 | +24.3% | 20,000 | 0.0% | 0.05% | +20.5% |
Q3 2016 | $136,000 | +126.7% | 20,000 | 0.0% | 0.04% | +116.7% |
Q2 2016 | $60,000 | +233.3% | 20,000 | +100.0% | 0.02% | +200.0% |
Q1 2016 | $18,000 | +5.9% | 10,000 | 0.0% | 0.01% | 0.0% |
Q4 2015 | $17,000 | +6.2% | 10,000 | 0.0% | 0.01% | 0.0% |
Q3 2015 | $16,000 | – | 10,000 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Ikarian Capital, LLC | 397,168 | $43,888 | 0.01% |
CJM Wealth Advisers, Ltd. | 30,465 | $3,366 | 0.00% |
Tekla Capital Management LLC | 154,310 | $17,051 | 0.00% |
McAdam, LLC | 10,006 | $6 | 0.00% |
Aries Wealth Management | 15,400 | $1,702 | 0.00% |
WELLS FARGO & COMPANY/MN | 342,084 | $37,800 | 0.00% |
JPMORGAN CHASE & CO | 43,415 | $5 | 0.00% |
NORTHERN TRUST CORP | 207,329 | $22,910 | 0.00% |
PINNACLE ASSOCIATES LTD | 18,580 | $2,053 | 0.00% |
CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |